Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

A formulation comprising:

• (i) about 10 mg/ml to about 200 mg/ml of an anti-TIGIT antibody, or antigen binding fragment thereof;
• (ii) about 5 mM to about 20 mM L-histidine or sodium acetate buffer;
• (iii) about 6% to about 8% weight/volume (w/v) sucrose or trehalose;
• (iv) about 0.01% to about 0.10% (w/v) polysorbate 80 or polysorbate 20;
• and
• (v) about 1 mM to about 20 mM L-methionine;
• and
• (vi) about 10 about 10 mg/ml to about 200 mg/ml anti-PD-1 antibody or antigen binding fragment thereof,
• wherein the formulation is a co-formulation,
• wherein the anti-PD-1 antibody or the antigen binding fragment thereof comprises three light chain CDRs comprising CDRL1 of SEQ ID NO:1, CDRL2 of SEQ ID NO:2 and CDRL3 of SEQ ID NO:3 and three heavy chain CDRs comprising CDRH1 of SEQ ID NO:6, CDRH2 of SEQ ID NO:7 and CDRH3 of SEQ ID NO:8, and
• wherein the anti-TIGIT antibody or the antigen binding fragment thereof comprises three light chain CDRs comprising CDRL1 of SEQ ID NO:
• 111, CDRL2 of SEQ ID NO:
• 112, and CDRL3 of SEQ ID NO:
• 113 and three heavy chain CDRs comprising CDRH1 of SEQ ID NO:
• 108, CDRH2 of SEQ ID NO:
• 154, and CDRH3 of SEQ ID NO:
• 110.